Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;7(5):244-51.
doi: 10.1177/1758834015587867.

Chemotherapy use in stage III colon cancer: a National Cancer Database analysis

Smrity Upadhyay  1 , Sumit Dahal  2 , Vijaya Raj Bhatt  3 , Nabin Khanal  4 , Peter T Silberstein  4
Affiliations

Chemotherapy use in stage III colon cancer: a National Cancer Database analysis

Smrity Upadhyay et al. Ther Adv Med Oncol. 2015 Sep.

Abstract

Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use.

Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ~70% of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy.

Results: A total of 35% of all stage III colon cancer patients, and 38% of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64% in 2007-2011 versus 59% in 2000-2002; p < 0.0001). Its use was lower in whites (61%), females (60%), patients ⩾60 years (55%), patients with one or more comorbidities (55%), nonacademic centers (62%), those with medicare insurance (52%), lower education (61%) and income levels (59%, all p < 0.0001). The nonwhite and uninsured were more likely to be <60 years old.

Conclusion: More than one-third did not receive adjuvant chemotherapy, although its use has increased in more recent years. Age was one of the most important determinants of chemotherapy use, which may explain higher rates in nonwhite and uninsured. In addition to patient characteristics, race, gender and socioeconomic factors influence chemotherapy use. These findings have important implications for healthcare reform.

Keywords: chemotherapy; disparities; stage III colon cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Peter T. Silberstein reports receiving payment for lectures from Bristol Myers and Celgene in the past. There are no conflicts of interest for any other authors.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351. - PubMed
    1. Andre T., Colin P., Louvet C., Gamelin E., Bouche O., Achille E., et al. (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896–2903. - PubMed
    1. Baldwin L., Dobie S., Billingsley K., Cai Y., Wright G., Dominitz J., et al. (2005) Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97: 1211–1220. - PMC - PubMed
    1. Bilimoria K., Stewart A., Winchester D., Ko C. (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15: 683–690. - PMC - PubMed
    1. Boland G., Chang G., Haynes A., Chiang Y., Chagpar R., Xing Y., et al. (2013) Association between Adherence to national comprehensive cancer network treatment guidelines and improved survival in patients with colon cancer. Cancer 119: 1593–1601. - PMC - PubMed